{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:42:30Z","timestamp":1786178550773,"version":"build-2736575974"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals USA Inc., Cambridge, MA, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09179-x","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:56:14Z","timestamp":1786175774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lanadelumab Use for Hereditary Angioedema Long-Term Prophylaxis Over the Last 7 Years: A Narrative Review of Clinical and Real-World Data"],"prefix":"10.1007","volume":"69","author":[{"given":"Paula","family":"Busse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zanichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Castaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Otule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"7","key":"9179_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E et al (2022) The international WAO\/EAACI guideline for the management of hereditary angioedema-the 2021 revision and update. Allergy 77(7):1961\u20131990. https:\/\/doi.org\/10.1111\/all.15214","journal-title":"Allergy"},{"issue":"14 Suppl","key":"9179_CR2","first-page":"S292","volume":"24","author":"JA Bernstein","year":"2018","unstructured":"Bernstein JA (2018) Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care 24(14 Suppl):S292\u2013S298","journal-title":"Am J Manag Care"},{"issue":"6","key":"9179_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.anai.2023.08.012","volume":"131","author":"SC Christiansen","year":"2023","unstructured":"Christiansen SC, Wilmot J, Castaldo AJ, Zuraw BL (2023) The US Hereditary Angioedema Association Scientific Registry: hereditary angioedema demographics, disease severity, and comorbidities. Ann Allergy Asthma Immunol 131(6):766\u2013774. https:\/\/doi.org\/10.1016\/j.anai.2023.08.012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"9179_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.anai.2013.08.019","volume":"111","author":"A Banerji","year":"2013","unstructured":"Banerji A (2013) The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol 111(5):329\u2013336. https:\/\/doi.org\/10.1016\/j.anai.2013.08.019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"9179_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","volume":"124","author":"A Banerji","year":"2020","unstructured":"Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J et al (2020) Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol 124(6):600\u2013607. https:\/\/doi.org\/10.1016\/j.anai.2020.02.018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"9179_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, de la Cruz M, Janssen E, Boysen HB, Jain G et al (2021) Clinical characteristics and burden of illness in patients with hereditary angioedema: Findings from a multinational patient survey. Orphanet J Rare Dis 16(1):94. https:\/\/doi.org\/10.1186\/s13023-021-01717-4","journal-title":"Orphanet J Rare Dis"},{"key":"9179_CR7","doi-asserted-by":"publisher","unstructured":"Craig TJ, Banerji A, Riedl MA, Best JM, Rosselli J, Hahn R et al (2021) Caregivers\u2019 role in managing hereditary angioedema and perceptions of treatment-related burden. Allergy Asthma Proc 42(3):S11\u201316. https:\/\/doi.org\/10.2500\/aap.2021.42.210029","DOI":"10.2500\/aap.2021.42.210029"},{"issue":"6","key":"9179_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2500\/aap.2024.45.240046","volume":"45","author":"J Anderson","year":"2024","unstructured":"Anderson J, Soteres D, Tachdjian R, Mellor J, Earl L, Connolly H et al (2024) Real-world outcomes in patients with hereditary angioedema prescribed lanadelumab versus other prophylaxis. Allergy Asthma Proc 45(6):426\u2013433. https:\/\/doi.org\/10.2500\/aap.2024.45.240046","journal-title":"Allergy Asthma Proc"},{"issue":"10","key":"9179_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1001\/archinte.163.10.1229","volume":"163","author":"K Bork","year":"2003","unstructured":"Bork K, Hardt J, Schicketanz K-H, Ressel N (2003) Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163(10):1229\u20131235. https:\/\/doi.org\/10.1001\/archinte.163.10.1229","journal-title":"Arch Intern Med"},{"issue":"1","key":"9179_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ et al (2021) US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract 9(1):132\u2013150. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.046","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"9179_CR11","doi-asserted-by":"publisher","first-page":"CD013403","DOI":"10.1002\/14651858.CD013403.pub2","volume":"11","author":"N Beard","year":"2022","unstructured":"Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K (2022) Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database Syst Rev 11(11):CD013403. https:\/\/doi.org\/10.1002\/14651858.CD013403.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"9179_CR12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s40265-019-01206-w","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY (2019) Lanadelumab: a review in hereditary angioedema. Drugs 79(16):1777\u20131784. https:\/\/doi.org\/10.1007\/s40265-019-01206-w","journal-title":"Drugs"},{"issue":"34","key":"9179_CR13","doi-asserted-by":"publisher","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","volume":"289","author":"JA Kenniston","year":"2014","unstructured":"Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ et al (2014) Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem 289(34):23596\u201323608. https:\/\/doi.org\/10.1074\/jbc.M114.569061","journal-title":"J Biol Chem"},{"key":"9179_CR14","unstructured":"U.S. Food and Drug Administration. Takhzyro. Prescribing information (2025).https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/spl-summaries\/criteria\/428217. Accessed 25 September 2025"},{"key":"9179_CR15","unstructured":"European Medicines Agency. Takhzyro. Summary of product characteristics (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/takhzyro-epar-product-information_en.pdf. Accessed 25 September 2025"},{"key":"9179_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/all.70207","author":"H Farkas","year":"2026","unstructured":"Farkas H, Martinez-Saguer I, Bork K, Germenis AE, Grumach AS, Horv\u00e1th HR et al (2026) International Guideline on the diagnosis and management of pediatric patients with hereditary angioedema. Allergy. https:\/\/doi.org\/10.1111\/all.70207","journal-title":"Allergy"},{"key":"9179_CR17","unstructured":"Takeda. US (2023) FDA approves Takeda\u2019s TAKHZYRO\u00ae (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/us-fda-approves-takedas-takhzyro-lanadelumab-flyo-to-prevent-hereditary-angioedema-hae-attacks-in-children-2-years-of-age-and-older\/. Accessed 6 March 2026"},{"issue":"3","key":"9179_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","volume":"77","author":"A Banerji","year":"2022","unstructured":"Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M et al (2022) Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. Allergy 77(3):979\u2013990. https:\/\/doi.org\/10.1111\/all.15011","journal-title":"Allergy"},{"issue":"8","key":"9179_CR19","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","volume":"376","author":"A Banerji","year":"2017","unstructured":"Banerji A, Busse P, Shennak M, Lumry W, Davis-Lorton M, Wedner HJ et al (2017) Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med 376(8):717\u2013728. https:\/\/doi.org\/10.1056\/NEJMoa1605767","journal-title":"N Engl J Med"},{"issue":"20","key":"9179_CR20","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL et al (2018) Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: A randomized clinical trial. JAMA 320(20):2108\u20132121. https:\/\/doi.org\/10.1001\/jama.2018.16773","journal-title":"JAMA"},{"issue":"11","key":"9179_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/1346-8138.16909","volume":"50","author":"M Hide","year":"2023","unstructured":"Hide M, Ohsawa I, Nurse C, Yu M (2023) SHP643-302 Trial Investigators. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study. J Dermatol 50(11):1381\u20131391. https:\/\/doi.org\/10.1111\/1346-8138.16909","journal-title":"J Dermatol"},{"issue":"1","key":"9179_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaip.2023.09.009","volume":"12","author":"M Maurer","year":"2024","unstructured":"Maurer M, Lumry WR, Li HH, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Busse PJ, Jacobs J et al (2024) Lanadelumab in patients 2 to less than 12 years old with hereditary angioedema: Results from the phase 3 SPRING study. J Allergy Clin Immunol Pract 12(1):201\u2013211. https:\/\/doi.org\/10.1016\/j.jaip.2023.09.009","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"9179_CR23","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.waojou.2022.100664","volume":"15","author":"M Abuzakouk","year":"2022","unstructured":"Abuzakouk M, Ghorab O, Al-Hameli H, Salvo F, Grandon D, Maurer M (2022) Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: A single-centre experience. World Allergy Organ J 15(7):100664. https:\/\/doi.org\/10.1016\/j.waojou.2022.100664","journal-title":"World Allergy Organ J"},{"key":"9179_CR24","doi-asserted-by":"publisher","first-page":"1405317","DOI":"10.3389\/fimmu.2024.1405317","volume":"15","author":"T Buttgereit","year":"2024","unstructured":"Buttgereit T, Vera Ayala C, Aykanat S, Weller K, Gutsche A, Maurer M et al (2024) The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center. Front Immunol 15:1405317. https:\/\/doi.org\/10.3389\/fimmu.2024.1405317","journal-title":"Front Immunol"},{"issue":"10","key":"9179_CR25","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1016\/j.jaip.2021.04.072","volume":"9","author":"T Buttgereit","year":"2021","unstructured":"Buttgereit T, Vera C, Weller K, Gutsche A, Grekowitz EM, Aykanat S et al (2021) Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study. J Allergy Clin Immunol Pract 9(10):3744\u20133751. https:\/\/doi.org\/10.1016\/j.jaip.2021.04.072","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"9179_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/all.15620","volume":"78","author":"AD Dorr","year":"2023","unstructured":"Dorr AD, Chopra C, Coulter TI, Dempster J, Dziadzio M, El-Shanawany T et al (2023) Lanadelumab for the prevention of hereditary angioedema attacks: a real-world UK audit. Allergy 78(5):1369\u20131371. https:\/\/doi.org\/10.1111\/all.15620","journal-title":"Allergy"},{"issue":"1","key":"9179_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13223-022-00664-4","volume":"18","author":"O Fain","year":"2022","unstructured":"Fain O, Du-Thanh A, Gobert D, Launay D, Inhaber N, Boudjemia K et al (2022) Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France. Allergy Asthma Clin Immunol 18(1):30. https:\/\/doi.org\/10.1186\/s13223-022-00664-4","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"10","key":"9179_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.36849\/JDD.2020.5269","volume":"19","author":"J Hahn","year":"2020","unstructured":"Hahn J, Trainotti S, Wigand MC, Schuler PJ, Hoffmann TK, Greve J (2020) Prospective analysis in patients with HAE under prophylaxis with lanadelumab: a real-life experience. J Drugs Dermatol 19(10):978\u2013983. https:\/\/doi.org\/10.36849\/JDD.2020.5269","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"9179_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13223-021-00579-6","volume":"17","author":"A Iaboni","year":"2021","unstructured":"Iaboni A, Kanani A, Lacuesta G, Song C, Kan M, Betschel SD (2021) Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada. Allergy Asthma Clin Immunol 17(1):78. https:\/\/doi.org\/10.1186\/s13223-021-00579-6","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"2","key":"9179_CR30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jaip.2024.12.008","volume":"13","author":"M Magerl","year":"2025","unstructured":"Magerl M, Bouillet L, Martinez-Saguer I, Gavini F, Bent-Ennakhil N, Sayegh L et al (2025) Real-world effectiveness of lanadelumab in hereditary angioedema: multicountry INTEGRATED observational study. J Allergy Clin Immunol Pract 13(2):378\u2013387. https:\/\/doi.org\/10.1016\/j.jaip.2024.12.008","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"9179_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000541242","volume":"186","author":"W Yao","year":"2025","unstructured":"Yao W, Diao R, Yang B, Wang Y, Li B, Li T et al (2025) Initial experience of long-term prophylaxis with lanadelumab for hereditary angioedema in China: a clinical observation study on six patients. Int Arch Allergy Immunol 186(3):221\u2013231. https:\/\/doi.org\/10.1159\/000541242","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"9179_CR32","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1007\/s12325-025-03226-3","volume":"42","author":"JA Bernstein","year":"2025","unstructured":"Bernstein JA, Betschel SD, Busse PJ, Banerji A, Wedner HJ, Manning M et al (2025) Sustained effectiveness, tolerability, and safety of long-term prophylaxis with lanadelumab in hereditary angioedema: the prospective, phase 4, noninterventional EMPOWER real-world study. Adv Ther 42(8):3882\u20133901. https:\/\/doi.org\/10.1007\/s12325-025-03226-3","journal-title":"Adv Ther"},{"issue":"1\u20133","key":"9179_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12016-024-09006-1","volume":"67","author":"HJ Longhurst","year":"2024","unstructured":"Longhurst HJ, Cancian M, Grivcheva-Panovska V, Koleilat M, Magerl M, Savic S et al (2024) Hereditary angioedema attacks in patients receiving long-term prophylaxis: a systematic review. Clin Rev Allergy Immunol 67(1\u20133):83\u201395. https:\/\/doi.org\/10.1007\/s12016-024-09006-1","journal-title":"Clin Rev Allergy Immunol"},{"key":"9179_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40801-025-00505-x","volume":"12","author":"M Watt","year":"2025","unstructured":"Watt M, Chang R, Yu LH, Clear L, DerSarkissian M (2025) Treatment patterns and characteristics of patients with hereditary angioedema treated with lanadelumab: a US retrospective chart review. Drugs Real World Outcomes 12:351\u2013365. https:\/\/doi.org\/10.1007\/s40801-025-00505-x","journal-title":"Drugs Real World Outcomes"},{"key":"9179_CR35","doi-asserted-by":"publisher","unstructured":"Zhi Y, Xu Y, Liu S, Wang X (2025) Chinese expert consensus on the diagnosis and treatment of hereditary angioedema (2024 edition). Chin J Allergy Clin Immunol 19(1):1\u201310. https:\/\/doi.org\/10.3969\/j.issn.1673","DOI":"10.3969\/j.issn.1673"},{"issue":"11","key":"9179_CR36","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1111\/all.14416","volume":"75","author":"MA Riedl","year":"2020","unstructured":"Riedl MA, Maurer M, Bernstein JA, Banerji A, Longhurst HJ, Li HH et al (2020) Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy 75(11):2879\u20132887. https:\/\/doi.org\/10.1111\/all.14416","journal-title":"Allergy"},{"issue":"10","key":"9179_CR37","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/cea.13974","volume":"51","author":"DT Johnston","year":"2021","unstructured":"Johnston DT, Busse PJ, Riedl MA, Maurer M, Anderson J, Nurse C et al (2021) Effectiveness of lanadelumab for preventing hereditary angioedema attacks: subgroup analyses from the HELP study. Clin Exp Allergy 51(10):1391\u20131395. https:\/\/doi.org\/10.1111\/cea.13974","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"9179_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13223-022-00721-y","volume":"18","author":"TJ Craig","year":"2022","unstructured":"Craig TJ, Zaragoza-Urdaz RH, Li HH, Yu M, Ren H, Juethner S et al (2022) Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies. Allergy Asthma Clin Immunol 18(1):85. https:\/\/doi.org\/10.1186\/s13223-022-00721-y","journal-title":"Allergy Asthma Clin Immunol"},{"key":"9179_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13601-017-0172-9","volume":"7","author":"MA Riedl","year":"2017","unstructured":"Riedl MA, Bernstein JA, Craig T, Banerji A, Magerl M, Cicardi M et al (2017) An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy 7:36. https:\/\/doi.org\/10.1186\/s13601-017-0172-9","journal-title":"Clin Transl Allergy"},{"key":"9179_CR40","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.anai.2024.08.001","volume":"133","author":"T Craig","year":"2024","unstructured":"Craig T, Tachdjian R, Bernstein JA, Anderson J, Nurse C, Watt M et al (2024) Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents. Ann Allergy Asthma Immunol 133:712\u2013719. https:\/\/doi.org\/10.1016\/j.anai.2024.08.001","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"12","key":"9179_CR41","doi-asserted-by":"publisher","first-page":"e14268","DOI":"10.1111\/pai.14268","volume":"35","author":"A Pagnier","year":"2024","unstructured":"Pagnier A, Dermesropian A, Kevorkian-Verguet C, Bourgoin-Heck M, Hoarau C, Reumaux H et al (2024) Hereditary angioedema in children: review and practical perspective for clinical management. Pediatr Allergy Immunol 35(12):e14268. https:\/\/doi.org\/10.1111\/pai.14268","journal-title":"Pediatr Allergy Immunol"},{"key":"9179_CR42","unstructured":"U.S. Food and Drug Administration. Haegarda. Prescribing information (2022). https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/spl-summaries\/criteria\/428210. Accessed 30 September 2025"},{"key":"9179_CR43","unstructured":"U.S. Food and Drug Administration. Cinryze. Prescribing information (2025). https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/spl-summaries\/criteria\/382466. Accessed 30 September 2025"},{"key":"9179_CR44","unstructured":"Takeda (2018) Shire announces FDA approval for label expansion of CINRYZE\u00ae (C1 esterase inhibitor [human]) for prevention of attacks in pediatric hereditary angioedema patients. https:\/\/www.takeda.com\/newsroom\/shire-news-releases\/2018\/7rr5re\/. Accessed 6 March 2026"},{"issue":"4","key":"9179_CR45","doi-asserted-by":"publisher","first-page":"100166","DOI":"10.1016\/j.jacig.2023.100166","volume":"2","author":"JCY Wong","year":"2023","unstructured":"Wong JCY, Chiang V, Lam DLY, Lee E, Lam K, Au EYL et al (2023) Long-term prophylaxis for hereditary angioedema: initial experiences with garadacimab and lanadelumab. J Allergy Clin Immunol Glob 2(4):100166. https:\/\/doi.org\/10.1016\/j.jacig.2023.100166","journal-title":"J Allergy Clin Immunol Glob"},{"key":"9179_CR46","doi-asserted-by":"publisher","unstructured":"Hoarau C, Maleki A, Bouillet L, Boccon-Gibod I (2024) Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series. Orphanet J Rare Dis 19(1):257. https:\/\/doi.org\/10.1186\/s13023-024-03251-5","DOI":"10.1186\/s13023-024-03251-5"},{"issue":"6","key":"9179_CR47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/1346-8138.17106","volume":"51","author":"C Hioki","year":"2024","unstructured":"Hioki C, Oda Y, Moriwaki S, Fukunaga A (2024) Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: report of five cases. J Dermatol 51(6):873\u2013877. https:\/\/doi.org\/10.1111\/1346-8138.17106","journal-title":"J Dermatol"},{"issue":"2","key":"9179_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5415\/apallergy.0000000000000102","volume":"13","author":"AG Bernardino","year":"2023","unstructured":"Bernardino AG, Ferreira MB, Costa C, Caiado J, Pedro E, Santos AS (2023) Experience of lanadelumab administration in hereditary angioedema: a case series of 4 patients in Portugal. Asia Pac Allergy 13(2):91\u201394. https:\/\/doi.org\/10.5415\/apallergy.0000000000000102","journal-title":"Asia Pac Allergy"},{"key":"9179_CR49","doi-asserted-by":"publisher","first-page":"110542","DOI":"10.1016\/j.clim.2025.110542","volume":"279","author":"HR Horv\u00e1th","year":"2025","unstructured":"Horv\u00e1th HR, Visy B, K\u0151halmi KV, Balla Z, Andrasi N, Czaller I et al (2025) A national survey of four decades of hereditary angioedema prophylaxis: efficacy and safety of old and new drugs. Clin Immunol 279:110542. https:\/\/doi.org\/10.1016\/j.clim.2025.110542","journal-title":"Clin Immunol"},{"key":"9179_CR50","doi-asserted-by":"publisher","first-page":"1636425","DOI":"10.3389\/falgy.2025.1636425","volume":"6","author":"NA Bara","year":"2025","unstructured":"Bara NA, N\u0103d\u0103\u0219an V, Deleanu D (2025) One-year real-life outcomes of lanadelumab therapy in Romanian patients with hereditary angioedema due to C1-inhibitor deficiency. Front Allergy 6:1636425. https:\/\/doi.org\/10.3389\/falgy.2025.1636425","journal-title":"Front Allergy"},{"issue":"3","key":"9179_CR51","doi-asserted-by":"publisher","first-page":"210","DOI":"10.5582\/irdr.2025.01045","volume":"14","author":"S Takamura","year":"2025","unstructured":"Takamura S, Fukuda T (2025) Three-year real-world outcomes of lanadelumab prophylaxis in hereditary angioedema: complete disease suppression and psychosocial benefits in two East Asian patients. Intractable Rare Dis Res 14(3):210\u2013215. https:\/\/doi.org\/10.5582\/irdr.2025.01045","journal-title":"Intractable Rare Dis Res"},{"issue":"1","key":"9179_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s13023-025-03988-7","volume":"20","author":"Y Xu","year":"2025","unstructured":"Xu Y, Guo Y (2025) A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumab. Orphanet J Rare Dis 20(1):441. https:\/\/doi.org\/10.1186\/s13023-025-03988-7","journal-title":"Orphanet J Rare Dis"},{"key":"9179_CR53","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/ced\/llae501","volume":"50","author":"J Teixeira","year":"2025","unstructured":"Teixeira J, Flor D, Xar\u00e1 J, Gon\u00e7alo M (2025) Successful lanadelumab dose spacing in type I hereditary angio-oedema. Clin Exp Dermatol 50:1034\u20131035. https:\/\/doi.org\/10.1093\/ced\/llae501","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"9179_CR54","doi-asserted-by":"publisher","first-page":"e70072","DOI":"10.1111\/pai.70072","volume":"36","author":"R Tachdjian","year":"2025","unstructured":"Tachdjian R, Banerji A, Busse PJ, Agmon-Levin N, Anderson J, Cancian M et al (2025) Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER\/ENABLE. Pediatr Allergy Immunol 36(4):e70072. https:\/\/doi.org\/10.1111\/pai.70072","journal-title":"Pediatr Allergy Immunol"},{"key":"9179_CR55","doi-asserted-by":"publisher","DOI":"10.1159\/000546987","author":"WR Lumry","year":"2025","unstructured":"Lumry WR, Davis-Lorton M, Soteres D, Earl L, Wynne-Cattanach K, Fox D et al (2025) Long-term real-world outcomes in patients with hereditary angioedema receiving lanadelumab for 3 or more years. Int Arch Allergy Immunol 187(3):289\u2013298. https:\/\/doi.org\/10.1159\/000546987","journal-title":"Int Arch Allergy Immunol"},{"key":"9179_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.07.025","author":"A Zanichelli","year":"2025","unstructured":"Zanichelli A, Wuillemin WA, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Banerji A, Busse PJ, Betschel SD et al (2025) Lanadelumab\u2019s impact on hereditary angioedema control and quality of life across disease activity subgroups: real-world evidence. Ann Allergy Asthma Immunol 135:560\u2013569.e2. https:\/\/doi.org\/10.1016\/j.anai.2025.07.025","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"9179_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40801-024-00470-x","volume":"12","author":"N Princic","year":"2025","unstructured":"Princic N, Evans KA, Shah CH, Sing K, Juethner S, Schultz BG (2025) Characteristics of patients with hereditary angioedema who reduced lanadelumab treatment administration frequency: a retrospective observational study of US claims data. Drugs Real World Outcomes 12(1):17\u201324. https:\/\/doi.org\/10.1007\/s40801-024-00470-x","journal-title":"Drugs Real World Outcomes"},{"key":"9179_CR58","doi-asserted-by":"publisher","first-page":"e240205","DOI":"10.57264\/cer-2024-0205","volume":"14","author":"N Princic","year":"2025","unstructured":"Princic N, Evans KA, Shah CH, Sing K, Juethner S, Schultz BG (2025) Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis. J Comp Eff Res 14:e240205. https:\/\/doi.org\/10.57264\/cer-2024-0205","journal-title":"J Comp Eff Res"},{"issue":"1","key":"9179_CR59","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/13696998.2023.2232260","volume":"26","author":"CH Shah","year":"2023","unstructured":"Shah CH, Princic N, Evans KA, Schultz BG (2023) Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab. J Med Econ 26(1):871\u2013877. https:\/\/doi.org\/10.1080\/13696998.2023.2232260","journal-title":"J Med Econ"},{"key":"9179_CR60","doi-asserted-by":"publisher","unstructured":"Riedl MA, Hinds DR, Prince PM, Alvord TM, Dosenovic S, Abdelhadi JF et al (2023) Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate. Allergy Asthma Proc 44(4):275\u2009\u2013\u200982. https:\/\/doi.org\/10.2500\/aap.2023.44.230026","DOI":"10.2500\/aap.2023.44.230026"},{"issue":"4","key":"9179_CR61","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14680","volume":"76","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Weller K, Magerl M, Banerji A, Longhurst HJ, Riedl MA et al (2021) Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP Study. Allergy 76(4):1188\u20131198. https:\/\/doi.org\/10.1111\/all.14680","journal-title":"Allergy"},{"issue":"1","key":"9179_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.anai.2023.03.028","volume":"131","author":"WR Lumry","year":"2023","unstructured":"Lumry WR, Maurer M, Weller K, Riedl MA, Watt M, Yu M et al (2023) Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema. Ann Allergy Asthma Immunol 131(1):101\u2013108. https:\/\/doi.org\/10.1016\/j.anai.2023.03.028","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"9179_CR63","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/all.14144","volume":"75","author":"K Weller","year":"2020","unstructured":"Weller K, Donoso T, Magerl M, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Staubach P, Martinez-Saguer I et al (2020) Development of the Angioedema Control Test-a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 75(5):1165\u20131177. https:\/\/doi.org\/10.1111\/all.14144","journal-title":"Allergy"},{"issue":"6","key":"9179_CR64","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.jaip.2020.02.038","volume":"8","author":"K Weller","year":"2020","unstructured":"Weller K, Donoso T, Magerl M, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Staubach P, Martinez-Saguer I et al (2020) Validation of the Angioedema Control Test (AECT)-a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract 8(6):2050\u20132057. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.038","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9","key":"9179_CR65","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/clt2.12295","volume":"13","author":"LM Fijen","year":"2023","unstructured":"Fijen LM, Vera C, Buttgereit T, Bonnekoh H, Maurer M, Magerl M et al (2023) Sensitivity to change and minimal clinically important difference of the Angioedema Control Test. Clin Transl Allergy 13(9):e12295. https:\/\/doi.org\/10.1002\/clt2.12295","journal-title":"Clin Transl Allergy"},{"issue":"10","key":"9179_CR66","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/all.12007","volume":"67","author":"K Weller","year":"2012","unstructured":"Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K et al (2012) Development and construct validation of the Angioedema Quality of Life Questionnaire. Allergy 67(10):1289\u20131298. https:\/\/doi.org\/10.1111\/all.12007","journal-title":"Allergy"},{"issue":"8","key":"9179_CR67","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/all.12900","volume":"71","author":"K Weller","year":"2016","unstructured":"Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M (2016) The Angioedema Quality of Life Questionnaire (AE-QoL) - assessment of sensitivity to change and minimal clinically important difference. Allergy 71(8):1203\u20131209. https:\/\/doi.org\/10.1111\/all.12900","journal-title":"Allergy"},{"key":"9179_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1477-7525-2-55","volume":"2","author":"JW Varni","year":"2004","unstructured":"Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P (2004) The PedsQL Family Impact Module: preliminary reliability and validity. Health Qual Life Outcomes 2:55. https:\/\/doi.org\/10.1186\/1477-7525-2-55","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"9179_CR69","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","volume":"113","author":"Y Chyung","year":"2014","unstructured":"Chyung Y, Vince B, Iarrobino R, Sexton D, Kenniston J, Faucette R et al (2014) A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol 113(4):460\u2013466. https:\/\/doi.org\/10.1016\/j.anai.2014.05.028","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9179_CR70","doi-asserted-by":"publisher","first-page":"885672","DOI":"10.3389\/fimmu.2022.885672","volume":"13","author":"R Mosch","year":"2022","unstructured":"Mosch R, Guchelaar H-J (2022) Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients. Front Immunol 13:885672. https:\/\/doi.org\/10.3389\/fimmu.2022.885672","journal-title":"Front Immunol"},{"issue":"1","key":"9179_CR71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.alit.2022.06.001","volume":"72","author":"BL Zuraw","year":"2023","unstructured":"Zuraw BL, Maurer M, Sexton DJ, Cicardi M (2023) Therapeutic monoclonal antibodies with a focus on hereditary angioedema. Allergol Int 72(1):54\u201362. https:\/\/doi.org\/10.1016\/j.alit.2022.06.001","journal-title":"Allergol Int"},{"issue":"12","key":"9179_CR72","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1089\/jir.2012.0139","volume":"34","author":"A Vultaggio","year":"2014","unstructured":"Vultaggio A, Nencini F, Pratesi S, Petroni G, Maggi E, Matucci A (2014) Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions. J Interferon Cytokine Res 34(12):946\u2013952. https:\/\/doi.org\/10.1089\/jir.2012.0139","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"9179_CR73","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.jaip.2018.04.007","volume":"6","author":"F Nencini","year":"2018","unstructured":"Nencini F, Vultaggio A, Pratesi S, Cammelli D, Milla M, Fiori G et al (2018) The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders. J Allergy Clin Immunol Pract 6(6):2065\u20132072. https:\/\/doi.org\/10.1016\/j.jaip.2018.04.007","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"14","key":"9179_CR74","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR et al (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460\u20131468. https:\/\/doi.org\/10.1001\/jama.2011.406","journal-title":"JAMA"},{"issue":"6","key":"9179_CR75","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/cts.12806","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, Marier J-F, Kassir N, Chang C, Martin P (2020) Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema. Clin Transl Sci 13(6):1208\u20131216. https:\/\/doi.org\/10.1111\/cts.12806","journal-title":"Clin Transl Sci"},{"issue":"4","key":"9179_CR76","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.anai.2025.01.007","volume":"134","author":"T Craig","year":"2025","unstructured":"Craig T, Baptist AP, Anderson J, Zaragoza-Urdaz RH, Burnette AF, Kelbel TE et al (2025) Hereditary angioedema: patient health care experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol 134(4):465\u2013473. https:\/\/doi.org\/10.1016\/j.anai.2025.01.007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"9179_CR77","doi-asserted-by":"publisher","unstructured":"Zuraw BL, Lopez-Gonzalez L, Manjelievskaia J, Winer I, Dean A, Wall S et al (2025) Adherence and persistence among patients with hereditary angioedema receiving long-term prophylaxis in the United States. Allergy Asthma Proc 46(3):209\u201317. https:\/\/doi.org\/10.2500\/aap.2025.46.250029","DOI":"10.2500\/aap.2025.46.250029"},{"issue":"5","key":"9179_CR78","doi-asserted-by":"publisher","first-page":"e12243","DOI":"10.1002\/clt2.12243","volume":"13","author":"AS Grumach","year":"2023","unstructured":"Grumach AS, Gadir N, Kessel A, Yegin A, Martinez-Saguer I, Bernstein JA (2023) Current challenges and future opportunities in patient-focused management of hereditary angioedema: a narrative review. Clin Transl Allergy 13(5):e12243. https:\/\/doi.org\/10.1002\/clt2.12243","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"9179_CR79","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13601-018-0229-4","volume":"8","author":"A Zanichelli","year":"2018","unstructured":"Zanichelli A, Magerl M, Longhurst HJ, Aberer W, Caballero T, Bouillet L et al (2018) Improvement in diagnostic delays over time in patients with hereditary angioedema: Findings from the Icatibant Outcome Survey. Clin Transl Allergy 8(1):42. https:\/\/doi.org\/10.1186\/s13601-018-0229-4","journal-title":"Clin Transl Allergy"},{"issue":"6","key":"9179_CR80","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40265-025-02180-2","volume":"85","author":"S Fung","year":"2025","unstructured":"Fung S (2025) Garadacimab: first approval. Drugs 85(6):827\u2013832. https:\/\/doi.org\/10.1007\/s40265-025-02180-2","journal-title":"Drugs"},{"key":"9179_CR81","unstructured":"U.S. Food and Drug Administration. Orladeyo. Prescribing information (2025) https:\/\/nctr-crs.fda.gov\/fdalabel\/ui\/spl-summaries\/criteria\/452865. Accessed 1 March 2026"},{"issue":"1","key":"9179_CR82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2023.09.039","volume":"153","author":"D Honda","year":"2024","unstructured":"Honda D, Li PH, Jindal AK, Katelaris CH, Zhi YX, Thong BY et al (2024) Uncovering the true burden of hereditary angioedema due to C1-inhibitor deficiency: a focus on the Asia-Pacific region. J Allergy Clin Immunol 153(1):42\u201354. https:\/\/doi.org\/10.1016\/j.jaci.2023.09.039","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"9179_CR83","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/cts.12778","volume":"13","author":"YR Shih","year":"2020","unstructured":"Shih YR, Liao KH, Chen YH, Lin FJ, Hsiao FY (2020) Reimbursement lag of new drugs under Taiwan\u2019s national health insurance system compared with United Kingdom, Canada, Australia, Japan, and South Korea. Clin Transl Sci 13(5):916\u2013922. https:\/\/doi.org\/10.1111\/cts.12778","journal-title":"Clin Transl Sci"},{"key":"9179_CR84","unstructured":"Department of Health, Disability and Ageing Pharmaceutical Benefits Scheme | Lanadelumab. https:\/\/www.pbs.gov.au\/medicine\/item\/12790E. Accessed 20 February 2026"},{"key":"9179_CR85","unstructured":"Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: Lanadelumab (Takhzyro \u2014 Shire Pharma Canada ULC). Canadian Agency for Drugs and Technologies in Health, Ottawa, ON (2019) Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558322\/. Accessed 20 February 2026"},{"key":"9179_CR86","unstructured":"CSL Behring (2026) ANDEMBRY\u00ae Summary of product characteristics. Accessed 1 March 2026 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/andembry-epar-product-information_en.pdf"},{"issue":"1","key":"9179_CR87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12016-025-09027-4","volume":"68","author":"BL Zuraw","year":"2025","unstructured":"Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE et al (2025) Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment. Clin Rev Allergy Immunol 68(1):24. https:\/\/doi.org\/10.1007\/s12016-025-09027-4","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"9179_CR88","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41584-020-0492-3","volume":"16","author":"KM Sullivan","year":"2020","unstructured":"Sullivan KM, Keyes-Elstein L (2020) Cross-trial comparisons in reviews: proceed with caution. Nat Rev Rheumatol 16(12):663\u2013664. https:\/\/doi.org\/10.1038\/s41584-020-0492-3","journal-title":"Nat Rev Rheumatol"},{"key":"9179_CR89","doi-asserted-by":"publisher","first-page":"b1147","DOI":"10.1136\/bmj.b1147","volume":"338","author":"F Song","year":"2009","unstructured":"Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 338:b1147. https:\/\/doi.org\/10.1136\/bmj.b1147","journal-title":"BMJ"},{"issue":"1","key":"9179_CR90","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T (2017) Network meta-analysis: an introduction for clinicians. Intern Emerg Med 12(1):103\u2013111. https:\/\/doi.org\/10.1007\/s11739-016-1583-7","journal-title":"Intern Emerg Med"},{"issue":"11","key":"9179_CR91","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jval.2023.07.001","volume":"26","author":"O Cassidy","year":"2023","unstructured":"Cassidy O, Harte M, Trela-Larsen L, Walsh C, White A, McCullagh L et al (2023) A comparison of relative-efficacy estimate(s) derived from both matching-adjusted indirect comparisons and standard anchored indirect treatment comparisons: a review of matching-adjusted indirect comparisons. Value Health 26(11):1665\u20131674. https:\/\/doi.org\/10.1016\/j.jval.2023.07.001","journal-title":"Value Health"},{"key":"9179_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.12.011","author":"C Olson","year":"2025","unstructured":"Olson C, Lionetti M, Poulos C, Ray T, Lopez-Gonzalez L, Nestler-Parr S et al (2025) Long-term prophylactic treatment preferences and willingness to switch therapy in individuals with hereditary angioedema. Ann Allergy Asthma Immunol 136(3):322\u2013332. https:\/\/doi.org\/10.1016\/j.anai.2025.12.011","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"9179_CR93","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jaip.2019.10.028","volume":"8","author":"BT Cheng","year":"2020","unstructured":"Cheng BT, Silverberg JI, Samet JD, Fishbein AB (2020) Burden of emergency department utilization and abdominal imaging for hereditary angioedema. J Allergy Clin Immunol Pract 8(4):1443\u20131446. https:\/\/doi.org\/10.1016\/j.jaip.2019.10.028","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"9179_CR94","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jaci.2021.02.034","volume":"147","author":"CM Davis","year":"2021","unstructured":"Davis CM, Apter AJ, Casillas A, Foggs MB, Louisias M, Morris EC et al (2021) Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A work group report of the AAAAI Committee on the Underserved. J Allergy Clin Immunol 147(5):1579\u20131593. https:\/\/doi.org\/10.1016\/j.jaci.2021.02.034","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9179_CR95","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/j.anai.2024.08.137","volume":"133","author":"A Baptist","year":"2024","unstructured":"Baptist A, Meadows J, Riedl M, Davis T, Robinson S, Huang Y et al (2024) Social determinants of health in hereditary angioedema and their impact on patient outcomes. Ann Allergy Asthma Immunol 133(6):S36\u2013S37. https:\/\/doi.org\/10.1016\/j.anai.2024.08.137","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09179-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09179-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:56:18Z","timestamp":1786175778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09179-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9179"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09179-x","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Paula Busse is a recipient of research support from ADARx, BioCryst, CSL Behring, Intellia, KalVista, and Takeda; recipient of consultancy fees from ADARx, Astria, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Pharvaris, and Takeda; and is a member of the Hereditary Angioedema Medical Advisory Board and US Hereditary Angioedema Association. Andrea Zanichelli is a recipient of speaker\/consultancy fees from Astria Therapeutics, BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming, Pharvaris, Otsuka, and Takeda. Jonathan Bernstein is a clinical investigator for ADARx, Astria, BioCryst, BioMarin Pharmaceutical, CSL Behring, Intellia, Ionis, KalVista Pharmaceuticals, Pharming Group, and Takeda; consultant for ADARx, Astria, BioCryst, BioMarin Pharmaceutical, CSL Behring, Intellia, Ionis, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Takeda; and a member of the Hereditary Angioedema Medical Advisory Board and US Hereditary Angioedema Association. John Anderson is a recipient of personal fees for steering committee, advisory board, speaker bureau, and\/or clinical research activity from BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Shire\/Takeda. Stephen Betschel is a recipient of speaker and\/or adviser fees from Astria Therapeutics, BioCryst, CSL Behring, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, and Takeda; and research funding from CSL Behring and Takeda. Daniel Castaner and Tara Piccolo are employees of Takeda Pharmaceuticals USA Inc., and hold stock\/stock options in Takeda Pharmaceutical Company Ltd. Matthew Otule was a former employee of Takeda Pharmaceuticals USA Inc. William Lumry is an advisory board member for Astria Therapeutics, BioCryst, BioMarin Pharmaceutical, CSL Behring, Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris, and Takeda; recipient of research grants from BioCryst, BioMarin Pharmaceutical, CSL Behring, Ionis, KalVista Pharmaceuticals, and Takeda; recipient of consulting fees from Astria Therapeutics, BioCryst, CSL Behring, Fresenius Kabi, Pharming Group, and Takeda; recipient of payments for lectures from CSL Behring, Pharming Group, and Takeda; and is an advisory board member of the US Hereditary Angioedema Association.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}